TABLE 5.
STATISTICAL ANALYSIS COMPARING BIOMARKER QUANTITIES BETWEEN HEALTHY SMOKERS AND SUBJECTS WITH STAGE 2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE, USING BOTH NORMALIZED AND NONNORMALIZED (RAW) DATA FROM THE SUBSET OF PATIENTS WHOSE SAMPLES WERE USED FOR 2-DGE
| 2-DGE Subset |
|||
|---|---|---|---|
| HS (n = 9) | COPD 2 (n = 12) | Exact Significance | |
| Normalized data | |||
| Apolipoprotein A1, μg/pdu | 8.19 (6.33–25.05) | 5.01 (3.15–6.53) | 0.002* |
| Albumin, μg/pdu | 0.691 (0.524–0.930) | 0.452 (0.349–0.699) | 0.023 |
| α2-HS glycoprotein, μg/pdu | 0.0046 (0.0034–0.0107) | 0.0031 (0.0019–0.004) | 0.058 |
| Transthyretin, ng/pdu | 1.075 (0.936–1.265) | 0.786 (0.525–1.360) | 0.382 |
| Lipocalin-1, ng/pdu | 12.89 (6.77–25.03) | 6.77 (3.61–17.71) | 0.082 |
| PLUNC, ng/pdu | 18.99 (8.15–24.96) | 39.35 (5.46–66.02) | 0.345 |
| PSP94, ng/pdu | 65.65 (40.11–128.75) | 85.46 (58.58–182.73) | 0.277 |
| Nonnormalized data | |||
| Apolipoprotein A1, μg/ml | 750.4 (505.4–2660.9) | 653.9 (394.9–784.6) | 0.193 |
| Albumin, μg/ml | 72.7 (52.3–104.2) | 58.9 (40.3–79.5) | 0.277 |
| α2-HS glycoprotein, μg/ml | 0.44 (0.29–1.66) | 0.36 (0.19–0.85) | 0.464 |
| Transthyretin, ng/ml | 95.5 (77.6–158.8) | 99.2 (59.4–143.7) | 0.917 |
| Lipocalin-1, ng/ml | 1,238.6 (907.3–2,720.4) | 1,068.4 (464.0–1,542.5) | 0.310 |
| PLUNC, ng/ml | 1,974.5 (1,144.8–2,283.9) | 3,789.8 (758.5–9,080.0) | 0.310 |
| PSP94, ng/ml | 7,442.1 (5,319.7–9,850.5) | 9,560 (6,708.7–20,609.3) | 0.148 |
Definition of abbreviations: α2-HS glycoprotein = α2-Heremans–Schmid glycoprotein; 2-DGE = two-dimensional gel electrophoresis; COPD 2 = stage 2 chronic obstructive pulmonary disease; HS = healthy smokers; pdu = pixel density unit; PLUNC = palate, lung, and nasal epithelium clone protein; PSP94 = prostate secretory protein of 94 amino acids.
Data were compared by Mann-Whitney U test; data values shown are medians (interquartile range in brackets). P values < 0.05 were considered significant.
P < 0.05.
P < 0.01.